Part 4: When Your Customer Is Anyone — or an AI — Anywhere: API Access and the Vanishing 'Infringer' [Paid]
The users of a medical AI web service are no longer confined to a single country. People everywhere can reach it — and increasingly, AI agents hit the service through its API rather than humans. Tellingly, even national patent-search systems now detect and block automated AI access.
"Who performed the act, and in which country?" — the foundational question of patent infringement — quietly collapses here. This article examines three forces driving that collapse: (1) how region settings and geo-redundancy erase the very location of execution and data, (2) how the 'infringer' becomes ambiguous when your customer is an AI or an API, and (3) the unique enforcement headaches this creates — viewed through both the engineering and the case law.
Read the full article
This is a premium article. A membership ($10/mo) unlocks every article (plus the full-series PDF once a series is complete), or buy just this one for $2 (48 hours), or the whole series for $7 (60 days; the full-series PDF is downloadable once all parts are published).
Please log in or sign up to subscribe or buy.
Log in / Sign up →
![Part 2: Can a Server Abroad Still Escape a Patent? Inside the Landmark Dwango v. FC2 Ruling [Paid]](/static/images/blog/fig/fig-medai-web-patent-strategy-2-cross-border-data-hero.png)
![Part 3: Does a Patent Really 'Reach' a Medical AI Service? The Architecture That Decides [Paid]](/static/images/blog/fig/fig-medai-web-patent-strategy-3-p3-hero.png)
![Part 4: When Your Customer Is Anyone — or an AI — Anywhere: API Access and the Vanishing 'Infringer' [Paid]](/static/images/blog/fig/fig-medai-web-patent-strategy-4-p4-hero.png)
![Part 5: How to Actually Protect a Medical-AI Web App in the Cloud Era (Series Finale) [Paid]](/static/images/blog/fig/fig-medai-web-patent-strategy-5-p5-hero.png)
![Part 3: How a University-Held 'Foundational Patent' Generated Fortunes — Two Legendary Patents That Succeeded for Opposite Reasons [Paid]](/static/images/blog/fig/fig-univ-medai-ip-cases-3-university-basic-patent-two-strategies.png)
![Part 2: When a Nobel-Winning Discovery Ended Up in Court — The University–Pharma Royalty Trap [Paid]](/static/images/blog/fig/fig-univ-medai-ip-cases-2-discovery-to-courtroom.png)
